Age-dependent Intrathecal Opioid Escalation in Chronic Noncancer Pain Patients

被引:34
|
作者
Hayek, Salim M. [1 ]
Veizi, I. Elias [1 ]
Narouze, Samer N. [2 ]
Mekhail, Nagy [2 ]
机构
[1] Case Western Reserve Univ, Div Pain Med, Dept Anesthesiol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[2] Cleveland Clin Fdn, Dept Pain Management, Cleveland, OH 44195 USA
关键词
Intrathecal Therapy; Opioid Dose Escalation; Opioids; Noncancer Pain; Age; Chronic Back Pain; Neuromodulation; CHRONIC NONMALIGNANT PAIN; RECEPTOR DESENSITIZATION; MORPHINE-TOLERANCE; INTRACTABLE PAIN; DRUG-DELIVERY; CHRONIC BACK; CANCER PAIN; INFUSION; MANAGEMENT; THERAPY;
D O I
10.1111/j.1526-4637.2011.01188.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background. Age and gender may exert important influences on opioid responsiveness and chronic pain. These effects have not been explored in the setting of chronic intrathecal (IT) opioid therapy. The objective of this study was to evaluate the effect of age and sex on IT opioid requirements during the first year after implantation of an intrathecal drug delivery system (IDDS) in chronic noncancer pain patients. Design. Retrospective study. Methods and Patient Population. In this retrospective study, 135 chronic noncancer pain patients consecutively implanted with IDDSs for opioid therapy had their first year postimplant records examined. Results. Similar pain relief was achieved at 12 months after implant in both age groups. Relative to the dose at implant, younger patients had significantly higher rates of IT opioid dose escalation compared with older patients at 12 months (750 +/- 450% in patients <= 50 years old vs 195 +/- 120% in patients >50 years old, P < 0.001). Oral opioid consumption was significantly decreased at 12 months in the older patient population (140 +/- 89 to 62 +/- 35 mg/day at 12 months, P < 0.001, n = 85), while in the younger patient group, there was no change in oral opioid consumption (128 +/- 81 mg/day to 105 +/- 140 mg/day at 12 months, P = 0.65, n = 50). Gender-based analysis (55% males and 45% females) revealed similar reductions in pain scores during the first year postimplant. Oral opioid consumption was significantly higher in females (126 +/- 138 mg) vs males (79 +/- 89 mg) at 12 months postimplant; however, IT opioid dose escalation at 12 months postimplant was not statistically different between males and females. Conclusion. IT opioid dose escalation occurs more steeply in the younger (under 50 years old) IDDS patient population without a concomitant significant decrease in oral consumption of opioids. Age-dependent changes may have important clinical implications on the effectiveness of IT opioid therapy in noncancer pain and its potential complications.
引用
收藏
页码:1179 / 1189
页数:11
相关论文
共 50 条
  • [41] Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
    BouSaba, Joelle
    Sannaa, Wassel
    Camilleri, Michael
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [42] Long-term opioid management for chronic noncancer pain
    Noble, M.
    Treadwell, J. R.
    Tregear, S. J.
    Coates, V. H.
    Wiffen, P. J.
    Akafomo, C.
    Schoelles, K. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
  • [43] Chronic Noncancer Pain and Opioid Addiction: Diagnostic and Management Challenges
    Kathiresan, Preethy
    Rao, Ravindra
    Joshi, Tanmay
    Bhad, Roshan
    Bhatnagar, Sushma
    Deb, Koushik Sinha
    Chadda, Rakesh Kumar
    INDIAN JOURNAL OF PALLIATIVE CARE, 2020, 26 (04) : 544 - 547
  • [44] Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
    Rauck, Richard L.
    Slatkin, Neal E.
    Stambler, Nancy
    Israel, Robert J.
    JOURNAL OF PAIN RESEARCH, 2019, 12 : 139 - 150
  • [45] Treatment Approaches for Patients With Opioid Use Disorder and Chronic Noncancer Pain: a Literature Review
    Eilender, Pamela
    Ketchen, Bethany
    Maremmani, Icro
    Saenger, Michael
    Fareed, Ayman
    ADDICTIVE DISORDERS & THEIR TREATMENT, 2016, 15 (02): : 85 - 98
  • [46] A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain
    Cryer, Byron
    Katz, Seymour
    Vallejo, Ricardo
    Popescu, Anca
    Ueno, Ryuji
    PAIN MEDICINE, 2014, 15 (11) : 1825 - 1834
  • [47] Chronic Opioid Use and Risk of Cancer in Patients with Chronic Noncancer Pain: A Nationwide Historical Cohort Study
    Oh, Tak Kyu
    Song, In-Ae
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (10) : 1962 - 1967
  • [48] Pain and disability in families of chronic noncancer pain patients
    Rodgers, C
    Levin, L
    Robeson, M
    Kunkel, EJS
    PSYCHOSOMATICS, 1996, 37 (05) : 476 - 480
  • [49] Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy
    Pergolizzi, Joseph V., Jr.
    Raffa, Robert B.
    Pappagallo, Marco
    Fleischer, Charles
    Pergolizzi, Joseph
    Zampogna, Gianpietro
    Duval, Elizabeth
    Hishmeh, Janan
    LeQuang, Jo Ann
    Taylor, Robert, Jr.
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 107 - 119
  • [50] Stability and Tolerability of High Concentrations of Intrathecal Bupivacaine and Opioid Mixtures in Chronic Noncancer Pain: An Open-Label Pilot Study
    Goucke, C. Roger
    Dusci, Leon J.
    Van Leeuwen, Shane
    Fairclough, Denise
    Lett, Ken F.
    PAIN MEDICINE, 2010, 11 (11) : 1612 - 1618